Roberts LR - Search Results

1

Factors that affect risk for hepatocellular carcinoma and effects of surveillance.

Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, Orsini L, Kim WR, Roberts LR. Yang JD, et al. Among authors: roberts lr. Clin Gastroenterol Hepatol. 2011 Jul;9(7):617-23.e1. doi: 10.1016/j.cgh.2011.03.027. Epub 2011 Apr 1. Clin Gastroenterol Hepatol. 2011. PMID: 21459158

2

Tumor seeding complicating radiofrequency ablation of hepatocellular carcinoma.

Decker GA, Gores GJ, Roberts LR. Decker GA, et al. Among authors: roberts lr. J Hepatol. 2003 May;38(5):692. doi: 10.1016/s0168-8278(03)00028-x. J Hepatol. 2003. PMID: 12713885 No abstract available.

3

hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling.

Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI, Greene EL, Shridhar V, Roberts LR. Lai JP, et al. Among authors: roberts lr. Gastroenterology. 2004 Jan;126(1):231-48. doi: 10.1053/j.gastro.2003.09.043. Gastroenterology. 2004. PMID: 14699503

4

A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures.

Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, Sebo TJ, Therneau TM, Gores GJ, de Groen PC, Baron TH, Levy MJ, Halling KC, Roberts LR. Kipp BR, et al. Among authors: roberts lr. Am J Gastroenterol. 2004 Sep;99(9):1675-81. doi: 10.1111/j.1572-0241.2004.30281.x. Am J Gastroenterol. 2004. PMID: 15330900

5

The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma.

Bonilla Guerrero R, Roberts LR. Bonilla Guerrero R, et al. Among authors: roberts lr. J Hepatol. 2005 May;42(5):760-77. doi: 10.1016/j.jhep.2005.02.005. J Hepatol. 2005. PMID: 15826727 Review. No abstract available.

6

Hepatocellular carcinoma: molecular pathways and new therapeutic targets.

Roberts LR, Gores GJ. Roberts LR, et al. Semin Liver Dis. 2005;25(2):212-25. doi: 10.1055/s-2005-871200. Semin Liver Dis. 2005. PMID: 15918149 Review.

7

MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients.

Baudhuin LM, Roberts LR, Enders FT, Swanson RL, Mettler TA, Aderca I, Stadheim LM, Highsmith WE. Baudhuin LM, et al. Among authors: roberts lr. J Cancer Res Clin Oncol. 2006 Mar;132(3):159-62. doi: 10.1007/s00432-005-0056-6. Epub 2005 Nov 15. J Cancer Res Clin Oncol. 2006. PMID: 16292541

8

SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.

Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR. Lai JP, et al. Among authors: roberts lr. Gastroenterology. 2006 Jun;130(7):2130-44. doi: 10.1053/j.gastro.2006.02.056. Gastroenterology. 2006. PMID: 16762634

9

Emerging drugs for hepatocellular carcinoma.

Roberts LR, Gores GJ. Roberts LR, et al. Expert Opin Emerg Drugs. 2006 Sep;11(3):469-87. doi: 10.1517/14728214.11.3.469. Expert Opin Emerg Drugs. 2006. PMID: 16939386 Review.

10

Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease.

Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN, Roberts RO, Roberts LR. Reddy A, et al. Among authors: roberts ro, roberts lr. Clin Gastroenterol Hepatol. 2007 Jan;5(1):118-23. doi: 10.1016/j.cgh.2006.07.011. Epub 2006 Sep 26. Clin Gastroenterol Hepatol. 2007. PMID: 17008133

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

519 results

Search Page